134 related articles for article (PubMed ID: 29110837)
1. The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Talbot T; Dangoor A; Shah R; Naik J; Talbot D; Lester JF; Cipelli R; Hodgson M; Patel A; Summerhayes M; Newsom-Davis T
Lung Cancer; 2017 Nov; 113():115-120. PubMed ID: 29110837
[TBL] [Abstract][Full Text] [Related]
2. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-tazobactam as a cost effective monotherapy in febrile neutropenia.
Fasih S; Siddiqui N; Muza N; Hannan A; Sarwar S; Shafi A; Athar S
J Ayub Med Coll Abbottabad; 2013; 25(3-4):19-22. PubMed ID: 25226731
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
7. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
8. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
Fouyssac F; Salmon A; Mansuy L; Schmitt C; Bordigoni P; Chastagner P
Med Mal Infect; 2005 Jun; 35(6):357-62. PubMed ID: 15982848
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
12. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia.
Watanabe N; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Cancer Chemother Pharmacol; 2015 Jul; 76(1):69-74. PubMed ID: 25976217
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Zengin E; Sarper N; Kılıç SC
Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
Gorschlüter M; Hahn C; Fixson A; Mey U; Ziske C; Molitor E; Horré R; Sauerbruch T; Marklein G; Schmidt-Wolf IG; Glasmacher A
Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
[TBL] [Abstract][Full Text] [Related]
20. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
